Coya Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Coya Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- COYA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001835022
Board of directors
-
Anabella Villalobos · DirectorSince 2023
-
Ann Lee · DirectorSince 2023
-
Arun Swaminathan · Director · Chief Executive OfficerSince 2024
-
Dieter Weinand · DirectorSince 2023
-
Dov A. Goldstein M.D. · DirectorSince 2023
-
Hideki Garren · DirectorSince 2023
-
Howard Berman · Director · Executive ChairmanSince 2023
-
Mark H. Pavao · DirectorSince 2026
-
Wilbur L. Ross Jr. · DirectorSince 2023
Chief executives
Howard Berman
· Chief Executive Officer
Dates unknown
Arun Swaminathan
· Chief Executive Officer
Dates unknown
Board connections
3 of this board's directors also sit on 3 other boards.
- via Howard Berman
- via Dov A. Goldstein M.D.
- via Dieter Weinand
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 18, 2025 | Dov A. Goldstein M.D. Director | Option exercise | +17,557 | $1.09 | $19,137 |
| Nov 14, 2024 | SNYDER DAVID S Officer (Chief Financial Officer) | Open-market purchase | +1,800 | $7.19 | $12,942 |
| Nov 13, 2024 | Arun Swaminathan Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $7.36 | $36,800 |
| Nov 11, 2024 | Grossman Fred Officer (Chief Medical Officer) | Open-market purchase | +2,710 | $7.37 | $19,973 |
| Nov 11, 2024 | Arun Swaminathan Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $7.34 | $36,700 |
| Aug 22, 2023 | Ann Lee Director | Open-market purchase | +1,000 | $3.62 | $3,620 |
| Jan 3, 2023 | Howard Berman Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Ann Lee Director | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Hepner Adrian Officer (Chief Medical Officer) | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Hideki Garren Director | Open-market purchase | +2,000 | — | — |
| Jan 3, 2023 | SNYDER DAVID S Officer (Chief Financial Officer) | Open-market purchase | +7,000 | — | — |
| Jan 3, 2023 | Anabella Villalobos Director | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Dov A. Goldstein M.D. Director | Open-market purchase | +10,000 | — | — |
| Jan 3, 2023 | Ann Lee Director | Derivative conversion | +6,479 | $4.00 | $25,916 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.